Home MarketAlkem Laboratories Ltd.

Alkem Laboratories Ltd. Stock Info: As on 2017-09-20 10:49:58

Nse

1774.00

-3.35(-0.19%)
Change%
52 Week Range
1,455.00
9.00
2,400.00
20.00
Open1,779.95
Day's Range1,421.88 - 2,132.82
Value Traded (in ₹ Cr.) 2.53

Bse

1768.00

-11.20(-0.63%)
Change %
52 Week Range
1,400.00
9.00
2,238.00
5.00
Open1,778.20
Day's Range1,423.36 - 2,135.04
Value Traded (in ₹ Cr.) 0.03

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 80,098,360.00 66.99%
Mutual Funds/UTI 2,633,430.00 2.20%
FII 5,039,544.00 4.21%
Employee 0.00 0.00%
Public 29,632,919.00 24.78%
Government 0.00 0.00%
Others 1,880,786.00 1.57%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 4.16
Basic EPS (Rs.) 53.40
Cash EPS 59.55
BVPerShare Excl 297.51
Operating Revenue 328.29
PBDITPerShare 73.01
Dividend 12.70
NPPerShare 53.40
Current Ratio 1.74
Quick Ratio 1.23
PriceToBV 4.59
Earnings 0.03
PBDIT Margin 22.23
PBT Margin 19.00
NP Margin 16.26
Return On Assets 13.15
Retention Ratios 76.21
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 4,085.21
Total Expenses 3,339.25
EBITDA 872.79
PBT 745.96
PAT 638.44
Net Income 638.44
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,932.73
Total Expenses 1,580.55
EBITDA 316.31
PBT 332.13
PAT 227.59
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 23.91
Net worth 3,556.70
Investments 1,071.13
Total Liability 4,853.33
Total debt 350.62
Net block 1,021.24
Total Assets 4,853.33
Parameter Sep-16 (₹ Cr.) 6M % change
Total share capital 23.91
Net worth 3,472.04
Investments 1,063.05
Total Liability 5,118.18
Total debt 872.21
Net block 987.26
Total Assets 5,118.18
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

533 536.2 -0.6
520.6544.45

Abbott India Ltd.

4145.05 4172.75 -0.66
40014206.05

Ajanta Pharma Ltd.

1199 1197.6 0.12
11821251.2

Albert David Ltd.

292.45 291 0.5
282.5307.35

Alembic Ltd.

38.75 38.75 0
38.1540

Alembic Pharmaceuticals Ltd.

481 482.95 -0.4
469.85515.85

Alpa Laboratories Ltd.

29.4 28.45 3.34
27.8530.35
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

114 115.1 -0.96
109.5127

Aarti Drugs Ltd.

533 537 -0.74
524540

Aayush Food & Herbs Ltd.

48.55 48.55 0
48.5548.55

Abbott India Ltd.

4160 4171.4 -0.27
40354202.5

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 629.81
Cash from investing activities 310.84
Cash from financing activities -958.16
Net change in cash -17.48

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Motilal Oswal MOSt Focused Multicap 35 Fund 2.47%
DSP BlackRock Small And Mid Cap Fund 1.73%
SBI Pharma Fund 4.56%
Motilal Oswal MOSt Focused Midcap 30 Fund 3.22%
Axis Emerging Opportunities Fund - Series 1 2.45%
Reliance Pharma Fund 0.87%

Infosys Finacle partners with Niki.ai

Infosys Finacle part of EdgeVerve Systems, a wholly-owned subsidiary of Infosys has partnered with Niki.ai, a FinTech start-up to offer chat based commerce to banking customers. With this partnership, Finacle solution suite will be available with Niki.ai's chat-based virtual assistant-Niki. This offering will enable banks to offer its customers a virtual banking assistant for shopping products and services. The joint solution from Finacle and Niki.ai will provide a smart-purchasing chatbot by leveraging natural language processing and machine learning to converse with customers and perform online transactions. The bot will comprehend natural speech text in the context of the customer and will deliver personalized suggestions. The solution will provide banks an opportunity to initiate two-way automated intelligent conversations with customers. Meanwhile, shares of the company closed trading at Rs 911.30 apiece, up 0.31 per cent from the previous close on BSE.

19-09-2017 16:56

Shriram Transport Finance raises Rs 50 cr via bonds

Shriram Transport Finance Company Ltd said it has raised Rs 50 crore by issuing Secured Redeemable Rated Listed Non-Convertible Debenture on private placement basis. “The Allotment Committee - NCDs of the Company in its meeting held today, approved and allotted 500 Secured Redeemable Rated Listed Non-Convertible Debenture of face value of Rs.10,00,000/- (Rupees Ten Lakh only) each, aggregating to Rs. 50 crore on private placement basis,” the company said in a filing to the Bombay Stock Exchange. The bonds with a tenor of 3 years, 11 months and 29 days, carries a coupon rate of 7.60 per cent per annum. Meanwhile, shares of the company closed trading at Rs 1072.65 apiece, down 1.27 per cent from the previous close on BSE.

19-09-2017 16:14

Tata Chemicals sells shares of Tata Global Beverages

Tata Group entity, Tata Chemicals said that it has sold entire shareholding of 4,31,75,140 equity shares of Tata Global Beverages to Tata Sons through a block deal. “The Company has today, i.e., September 19, 2017, sold 4,31,75,140 Equity Shares of face value of Rs. 1/- each of Tata Global Beverages Limited to Tata Sons Limited at price of Rs. 213.35 per share,” it said in a filing to the Bombay Stock Exchange. The chemical company sold these shares at a price of Rs 213.35 per share (excluding brokerage and STT). Promoter group's shareholding stood at 35.76 per cent stake in Tata Global as of June 2017, including Tata Sons' stake of 23.5 per cent that increased to over 30 per cent post block deal. Meanwhile, shares of Tata Chemicals closed trading at Rs 656.95 apiece, up 2.24 per cent from the previous close on BSE.

19-09-2017 15:55

KPTL raises Rs 100 cr on private placement basis

Kalpataru Power Transmission Ltd said that it has raised Rs 100 crore by issuing Non-Convertible Debentures on private placement basis. “The executive committee of board of directors of the company at its meeting held today has approved issuance of listed, rated, unsecured redeemable taxable non convertible debentures of Rs 100 crore on private placement basis,” the company said in a filing to the Bombay Stock Exchange. The bonds carrying a coupon rate of 8.11 per cent p.a. are proposed to be listed on wholesale debt market segment of BSE Ltd. The debentures having a tenure of 5 years from the deemed date of allotment will mature on 27th September 2022, the filing added. Meanwhile, shares of the company closed trading at Rs 362.50 apiece, up 2.13 per cent from the previous close on BSE.

19-09-2017 15:46

Cadila Healthcare enters into agreement with Pharm Aid

Cadila Healthcare Limited, an innovation-driven global healthcare company has said that it has entered into an exclusive agreement for the technology know-how for varicella vaccine production in the Russian Federation with Pharm Aid Ltd., headquartered in Russia. The exclusive agreement was signed at the BIOTECHMED conference in Gelendzhik, Russia. Pharm Aid Ltd, has been set up by Nacimbio together with Ishvan Pharmaceuticals Ltd., for the localization of innovative vaccine production in Russia. Through this agreement, Zydus gains access to the public and private market segments in the Russian Federation, Belarus, Uzbekistan, Kazakhstan, Armenia and Kyrgyzstan. With an absence of assured supply of indigenously manufactured varicella vaccine, this vaccine does not feature currently in the National Immunisation Programme. The agreement aims to bring in a continuous supply of vaccines which could be included in the critical childhood immunization programme. The demand is estimated at 3 million doses per annum in the Russian Federation alone. Meanwhile, shares of the company were trading at Rs 485.50 apiece, down 0.22 per cent from the previous close at 15:11 hours on BSE.

19-09-2017 15:05

USFDA issues two 483 observations for Alkem’s Baddi facility

Pharma major, Alkem Laboratories said that it has received inspection report from USFDA, which contains two 483 observations for Alkem’s Baddi facility. USFDA had conducted an inspection at the company's manufacturing facility located at Baddi, India from September 11-15, 2017, the company said in a filing to the Bombay Stock Exchange. The company shall put together a detailed response with adequate corrective and preventive measures to address the USFDA observations and the same is proposed to be filed within the timeline stipulated by USFDA. The company had reported 70 percent fall in net profit to Rs 71.6 crore in the first quarter ended June. Revenues declined 12.5 percent to Rs 1295.2 crore. Meanwhile, shares of the company were trading at Rs 1785.50 apiece, down 1.26 per cent from the previous close at 11:40 hours on BSE.

18-Sep-2017 11:37 AM

Alkem Laboratories - Press Release

Alkem Laboratories Limited has informed the Exchange regarding a press release dated September 18, 2017, titled Update on US FDA Inspection at Alkem?s Baddi Facility .

18-Sep-2017 09:42 AM

Alkem Laboratories - Press Release / Media Release

Update on US FDA Inspection at Alkem's Baddi Facility -

This is to inform you that US FDA had conducted an inspection at the Company's manufacturing facility located at Baddi, India from 11th September, 2017 to 15th September, 2017.

In this regard, the Company has received the inspection report which contains two 483 observations. The Company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA Observations and the same is proposed to be filed within the timeline stipulated by US FDA.

18-Sep-2017 09:41 AM

Alkem Laboratories - Shareholders meeting

Alkem Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 08, 2017. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.

08-Sep-2017 05:25 PM

Alkem Laboratories - Outcome of AGM

Outcome of the 43rd Annual General Meeting of the Company and Disclosure of Voting Results thereat.

This is with reference to the 43rd Annual General Meeting of the Company held today i.e. on Friday, 8th September, 2017 at 10.30 a.m. at Nehru Centre Auditorium, Dr Annie Besant Road, Worli, Mumbai 400 018.

Pursuant to Regulation 30 of the SEBI LODR Regulations, we are submitting herewith the details regarding the brief proceedings of the 43rd Annual General Meeting (AGM) of the Company.

Pursuant to Regulation 44(3) of the SEBI LODR Regulations, 2015, we are also submitting herewith the details regarding the voting results of the business transacted at the said AGM in the prescribed format.

Further, we are also enclosing the Report of the Scrutinizer on e-voting and voting through ballot forms at the AGM.

You are requested to take a note of the same and bring it to the notice of all concerned.

08-Sep-2017 05:24 PM

Alkem Laboratories - Press Release / Media Release

Update on US FDA Inspection at Alkem's Baddi Facility -

This is to inform you that US FDA had conducted an inspection at the Company's manufacturing facility located at Baddi, India from 11th September, 2017 to 15th September, 2017.

In this regard, the Company has received the inspection report which contains two 483 observations. The Company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA Observations and the same is proposed to be filed within the timeline stipulated by US FDA.

18-Sep-2017 09:41 AM

Alkem Laboratories - Outcome of AGM

Outcome of the 43rd Annual General Meeting of the Company and Disclosure of Voting Results thereat.

This is with reference to the 43rd Annual General Meeting of the Company held today i.e. on Friday, 8th September, 2017 at 10.30 a.m. at Nehru Centre Auditorium, Dr Annie Besant Road, Worli, Mumbai 400 018.

Pursuant to Regulation 30 of the SEBI LODR Regulations, we are submitting herewith the details regarding the brief proceedings of the 43rd Annual General Meeting (AGM) of the Company.

Pursuant to Regulation 44(3) of the SEBI LODR Regulations, 2015, we are also submitting herewith the details regarding the voting results of the business transacted at the said AGM in the prescribed format.

Further, we are also enclosing the Report of the Scrutinizer on e-voting and voting through ballot forms at the AGM.

You are requested to take a note of the same and bring it to the notice of all concerned.

08-Sep-2017 05:24 PM

Alkem Laboratories - Clarifies on News item

With reference to news in www.moneycontrol.com dated August 23, 2017 quoting Alkem Labs gets US FDA nod for rhinitis drug, Azelastine Hydrochloride Spray. Alkem Laboratories Ltd has submitted to BSE a copy of Clarification is enclosed.

23-Aug-2017 02:03 PM

Corporate Details

About Management

The Company was incorporated as a private limited company `Alkem Laboratories Private Limited' on August 8,1973 at Patna under the Companies Act, 1956 and subsequently became a deemed public limited company under section 43A(2) of Companies Act, 1956 on October 26, 1988. Pursuant to the Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of the Company was changed to `Alkem Laboratories Limited' with effect from October 26, 1988. the registered office was originally located at `Exhibition Road, Patna - 800 001, Bihar, India'. the Company filed Company Petition No. 356(17)/ ERB/ 2007 before the Company Law Board, Eastern Region Bench at Kolkata for shifting the registered office of the Company from the State of Bihar to the State of Maharashtra, as approved by a special resolution at its extra-ordinary general meeting held on January 29, 2007. The Company Law Board, Eastern Region Bench at Kolkata passed an order dated July 30, 2007 whereby it confirmed the alteration of the situation clause in the Memorandum of Association, from the State of Bihar to the State of Maharashtra. Pursuant to the order, the registered office of the Company was shifted to `Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013, Maharashtra, India' with effect from August 2, 2007. Major Events : 1973 -Incorporation of the Company. 1978 -the Company established its first plant at Taloja, Maharashtra. 1988 -the Company became a deemed public limited company. 1992 -the Company established its manufacturing facility in Mandwa, Maharashtra. This facility was converted into an API facility in 2005. 1998 -the Company established its Kachigam manufacturing facility in Gujarat. 2001 -Startronic Pharmachem Private Limited and Indo Propkem amalgamated with the Company. 2002 -the Company established its Amaliya manufacturing facility in Gujarat. 2003 -the Company set up its research and development facility at Taloja, Maharashtra. 2005 -the Company established its manufacturing facility in Baddi, Himachal Pradesh. 2006 -the anti-infective drug Taxim became the first drug in the Indian pharmaceutical industry to cross 1,000 million in terms of domestic sales in India (Source: IMS Research) 2007 -the Company established its manufacturing facility in Kumrek, Sikkim. -the Company filed its first ANDA in the United States for the drug, Amlodipine. -the Company shifted its Registered Office from Patna, Bihar to Mumbai, Maharashtra. 2009 -the Company acquired Pharmacor, a generic pharma company in Australia. 2010 -the Company acquired The PharmaNetwork, LLC, the holding company of Ascend Laboratories LLC. 2011 -the Company acquired Enzene Bio sciences Limited. 2012 -the Company acquired an API manufacturing facility in the United States. 2014 -the Company acquired the Clindac. 2015 -the Company acquired a formulation manufacturing facility in the United States. Awards and achievements: 2002 -the Company was awarded the Pharma Business and Technology Excellence Award in 2002 as 'India's Most Esteemed Pharmaceutical Company' 2004 -the product Taxim was awarded the Pharma Business and Technology Excellence Award for successful brand in 2004 2005 -the Company was awarded the Overall Performance Award for Group B at the 5th Express Pharma Awards in 2005 2009 -the Company received a certificate of appreciation for outstanding export performance in the category of formulations by the Pharmaceuticals Export Promotion Council of India, supported by Ministry of Commerce and Industry, GOI -the Company received the certificate of appreciation in the category of `Formulation Experts' by the Pharmaceuticals Export Promotion Council of India, supported by Ministry of Commerce and Industry, GOI 2013 -the Company was awarded the India's most admired pharma company award for 2013 at the 6th Annual Pharmaceutical Leadership Summit in 2013 2014 -the Product `Clavam' was awarded as the ` Brand of the Year' at the AWACS Award, 2014 2016 -Alkem's Mandva Plant successfully obtains the Establishment Inspection Report from the US FDA -Alkem receives EIR from the US FDA for its Daman formulation facility

Registered Office

MIDC, Taloja

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.